Publication Month: Mar 2018 | Report Code: TIPHE100000820 | No. of Pages: 278 | Category: Healthcare IT | Status: Published
Next-generation sequencing (NGS), also known as high-throughput sequencing. NGS enables rapid sequencing of the base pairs in DNA or RNA samples. NGS is driving discovery and enabling the future of personalized medicine, genetic diseases, and clinical diagnostics. However, in this research study, the products of NGS have been classified into three broad segments as consumables, services and platforms.
The next generation sequencing market is segmented on the bases of products, technology, application, end user, and geography. By geography, the market is broadly segmented into North America, Europe, Asia Pacific, the Middle East and Africa, and South and Central America. The report offers insights and in-depth analysis of the market, emphasizing on parameters such as market trends, technological advancements, and market dynamics along with the analysis of competitive landscape of world’s leading market players.
Get more information on this report :
In the recent years, next generation sequencing price have declined substantially. For instance, first whole human genome sequencing cost over US$3.7 billion in 2000 and took 13 years for the completion. However, the costs for the same in recent years has reduces to US$1,000 and the process requires less number of days. In 2000, cost for sequencing was US$ 3.7 billion, which dropped down to US$ 10 million in 2006 and declined to US$ 5,000 in 2012. Major market players such as Illumina and Roche have introduced breakthrough technologies that have enabled in the cost and time reduction in the sequencing.
Owing to factors such as advances in the field of genomics, development in different methods and strategies for sequencing, there is a notable decline in the cost of sequencing.
Advancement in the field of molecular biology has equally enhanced the sequencing procedures. Many industry players have come up with innovative NGS technology in last few years. For instance, Pacific Biosciences with Sequel, and Oxford Nanopore with PromethION. Additionally, three advances NSG systems that dominate the market includes Roche GS FLX (454), Illumina HiSeq 2000 (Solexa) and AB SOLiD (Agencourt).
Further modification and automation of this process continued to increase sequencing data and time reduction. Thereby allowing researchers to reach major milestones in the Human Genome Project. NGS makes sequence based gene expression analysis a “digital” alternative to analog techniques. It also aids in quantifying RNA expression with the breadth of a microarray and the resolution of qPCR.
Advancement in genome sequencing has made the sequencing easy and accurate. These technological advancement are likely to grow the market in near future.
Based on products, the next generation sequencing market is segmented into consumables, services, and platforms. In 2016, the consumables segment held the largest share of the market and is expected to grow at the highest CAGR during 2016–2025. The consumables are used in the numerous stages of the next generation sequencing procedures which include sample generation, storing the samples and its purification, preparation of the library and quantification, and PCR amplification. The consumables offered by various companies are widely accepted by the consumers and it provides accuracy and precision in the preparation of the next generation sequencing which is major factor for the growth of the segment in the next generation sequencing market.
Based on technology, the next generation sequencing market is segmented into genome sequencing, exome sequencing, resequencing & targeted sequencing and other. The resequencing & targeted sequencing segment held the largest market share in 2016, and it is further expected to be the largest shareholder in the market by 2025. In targeted resequencing, a subset of genes or regions of the genome are isolated and sequenced. Targeted methods which use NGS allows the researchers in focusing on the time, expenses, and data analysis on specific areas of interest. The growing funding by various government bodies and usage of next generation sequencing in the resequecing and targeted sequencing which is bolstering the market growth of this segment.
Based on application, the global next generation sequencing market is segmented into diagnostics, drug discovery, precision medicine and others. In 2016, the diagnostics segment held the largest share of the market. Moreover, the market for the silicone segment is expected to grow at the highest CAGR during 2016–2025. The use of next-generation sequencing (NGS) technology in the diagnostic genome care needs precision and accuracy. The NGS technologies use sequencing which are cost efficient to gain genomic information about the patients from the whole-genome sequencing to perform the clinical actions. The various advantages of NGS include testing many genes in one go and relatively short time and at lower costs. This enables maximum number of NGS diagnostic procedures in short span of time. The new technological advanced machines have led towards the prime growth rate of the diagnostics next generation sequencing market
Based on end user, the global next generation sequencing market is segmented into academic & research institutes, pharmaceutical & biotechnology companies, hospitals & clinics and others. In 2016, the academic & research institutes segment held the largest share of the market and it is further expected to be the largest shareholder in the market by 2025. Many of the organizations have formed due to the partnerships between various organizations and universities for research in the transformation of scientific technologies to make the life-saving treatments for patients. The academic & research institutes are getting funds from the various organizations for the research and development sector for the betterment of NGS. The funding for the academic & research institutes have boosted the market share for the segment in the NGS market.
Get more information on this report :
Product launches, and mergers and acquisitions are the highly adopted strategies by the players operating in the global next generation sequencing market. A few of the recent key product developments are listed below:
In January 2018, Illumina, Inc. launched iSeq 100 sequencing system, known to deliver exceptional data accuracy at low cost, which makes Illumina technology available to any lab.
In February 2018, Thermo Fisher Scientific launched the Applied Biosystems Axiom Microbiome Array for simultaneous detection of fungi, protozoa, bacteria, archea, and viruses in human samples. With the launch, orthogonal approach to interpretation of diverse microbiota has become possible.
Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.